
- Huadong Medicine reported a net income of 914.7 million yuan for the first quarter of 2025.
- This marks a 6.1% increase in net income compared to the same period last year, when it was 862.4 million yuan.
- The company’s revenue for this quarter was 10.74 billion yuan.
- This revenue signifies a 3.2% increase from the previous year.
- Analyst ratings on the company include 23 “buy” recommendations, 1 “hold,” and 1 “sell.”
A look at Huadong Medicine Co Ltd A Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Huadong Medicine Co Ltd A shows promising long-term prospects. With solid scores in Dividend, Growth, Resilience, and Momentum, the company appears well-positioned for future success. A high score in Dividend indicates the company’s ability to generate stable returns for its investors. The strong Growth score highlights the potential for expansion and increasing market value. Additionally, a high Momentum score suggests positive investor sentiment and a favorable market outlook. Although the Value score is moderate, the overall outlook for Huadong Medicine Co Ltd A seems positive.
Huadong Medicine Co., Ltd. is engaged in wholesaling and retailing a variety of healthcare products, including medicines, pharmaceutical preparations, biological products, and medical instruments. The company, through its subsidiaries, is also involved in the manufacturing of antibiotic medicines and biochemical products. With a balanced blend of product offerings and a focus on both wholesale and retail channels, Huadong Medicine Co., Ltd. has established a diversified presence in the healthcare industry, positioning itself for potential growth and sustainability in the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars